Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2024-04-24 Management Reports
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司2024年“提质增效重回报”行动方案
Management Reports Classification · 95% confidence The document is titled as a 2024 action plan by Chengdu Lead Drug Development Co., Ltd. It outlines the company's current status, strategic initiatives, business development, investor relations, governance, and management incentive plans. It includes detailed descriptions of business operations, financial performance highlights for 2023, and plans for 2024. The document is comprehensive and contains substantive business and financial information but does not present formal financial statements or detailed financial data typical of an Annual Report (10-K) or Interim Report (IR). It is not a short announcement or a certification but a detailed strategic and operational plan document. It does not fit into categories like earnings release, call transcript, or regulatory filings. The content aligns best with a Management Report (MDA) as it provides management's detailed explanation of business trends, financial results, and outlook, including strategic plans and governance information.
2024-04-24 Chinese
成都先导药物开发股份有限公司关于德勤华永会计师事务所（特殊普通合伙）履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of Deloitte Huayong CPA Firm in their role as the auditor for Chengdu Lead Drug Development Co., Ltd. for the fiscal year 2023. It details the auditor's qualifications, quality management systems, audit procedures, independence, and compliance with relevant regulations. The document references the 2023 annual financial report audit but does not contain the financial statements or substantive financial data itself. It is a standalone audit performance evaluation report, not the full annual report or audit report. The document length is 4757 characters, which is substantial but focused on audit firm evaluation rather than financial results. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and evaluations of audit firms' performance, excluding full annual reports.
2024-04-24 Chinese
成都先导药物开发股份有限公司2023年年度报告
Annual Report Classification · 100% confidence The document is titled '2023 年年度报告' which translates to '2023 Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The presence of an audit report by Deloitte with an unqualified opinion is mentioned, and the document spans 261 pages, indicating a comprehensive report. The content includes detailed financial metrics, quarterly breakdowns, non-recurring items, and management commentary, all typical of a full annual report. There is no indication that this is merely an announcement or a summary; it is the full report itself. Therefore, the document fits the definition of an Annual Report (10-K).
2024-04-24 Chinese
成都先导药物开发股份有限公司关于作废部分已授予尚未归属的2023年限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Chengdu Lead Drug Development Co., Ltd. regarding the cancellation of part of the 2023 restricted stock awards that have been granted but not yet vested. It details the board and supervisory approvals, the reasons for cancellation (employee departure and unmet performance targets), and legal opinions confirming compliance with regulations. The document is focused on a corporate action related to equity incentive plans and does not contain financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or management discussion. It is a regulatory announcement about a capital change related to share awards. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is 3271 characters, which is consistent with an announcement rather than a full report.
2024-04-24 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2023年度募集资金存放与使用情况的专项核查意见
Regulatory Filings
2024-04-24 Chinese
成都先导药物开发股份有限公司关于使用部分暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the board of directors of Chengdu Lead Drug Development Co., Ltd. regarding the use of temporarily idle self-owned funds for cash management. It details the amount, types of financial products, duration, risk analysis, and approval procedures. The document is an announcement of a financing or capital management activity rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data but rather informs shareholders and the public about the company's cash management plan and related board approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (2022 characters), and it is not a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2024-04-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.